Category Uncategorized

Researcher Spotlight: Tianfang Ma, PhD Dana-farber cancer institute Health Equity Initiative Immunotherapies that activate the immune system against cancer cells have yielded promising results for many patients with diffuse large B-cell lymphoma (DLBCL), but not all people respond to treatment.…

Researcher Spotlight: Etienne Leveille, MD yale university Ferroptosis is a type of cell death to which therapy-resistant cancer cells have been found to be highly sensitive. Lymphomas, including diffuse large B-cell lymphoma (DLBCL), are among the most ferroptosis-sensitive types of…

Researcher Spotlight: Michelle Lee, MD, PhD emory university Black patients with diffuse large B-cell lymphoma (DLBCL) tend to have worse outcomes than patients from other groups. These differences may be due to a combination of biological and genetic factors, but…

Researcher Spotlight: Kazuya Fukasawa, PhD memorial sloan kettering cancer center Condon Family Fellow The introduction of bispecific antibodies represents a promising therapeutic advancement in the treatment of lymphoma. These therapies work by redirecting T-cells to interact with tumor cells, supporting…

Researcher Spotlight: Pantaleo De Simone, MD columbia university irving medical center Diffuse large B-cell lymphoma (DLBCL) is an aggressive and often incurable form of lymphoma. An improved understanding of DLBCL biology is needed to identify potential treatment strategies, and Dr.…

Researcher Spotlight: Robert Stuver, MD memorial sloan kettering cancer center Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is an aggressive T-cell lymphoma that primarily occurs in young adults. Many patients can be cured with chemotherapy, but if the…

Researcher Spotlight: Paola Ghione, MD memorial sloan kettering cancer center Skin infections and bacterial colonization are known to play an important role in the development and severity of cutaneous T-cell lymphomas (CTCLs). Topical treatments, including bleach baths and antiseptic creams,…

Researcher Spotlight: Jordan Goldstein, MD Leland stanford Junior University Despite effective options for first-line treatment, many people with diffuse large B-cell lymphoma (DLBCL) still experience relapse. Novel chimeric antigen receptor (CAR) T-cell therapies are often used after relapse in DLBCL,…